Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun receives FDA nod for two generic drugs

 

SUN Pharmaceutical Industries said it has received approval from US health regulator (USFDA) to market generic Clarinex tablets and Tiazac capsules, used in treating nasal al'lergies and hypertension, respectively, in the American market. The Mumbai-based firm has received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to market a ge'neric version of Schering Plough's Clarinex tablets, Sun Pharma said in a statement.
 
The company has received the approval for generic Clarinex tablets in the strength of 5 mg. The tablets are indicated for allergic rhinitis or allergic- inflammation of the nasal airways, it said. Allergic Rhinitis occurs when an allergen such as pollen or dust is inhaled by an individual with a sensitised immune system and triggers antibody production. Clarinex tablets (5 mg) have annual sales of nearly $212 million in the US, it said.
 
In a separate statement, the company said it has received approval from USFDA for generic Tiazac capsules used for treating high blood pressure.